AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16507398
Drug: exemestane 25
RxNorm normalized name: exemestane 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: exemestane 25 mg daily (Group B)
Trial: 16507398
Drug: letrozole 2.5
RxNorm normalized name: letrozole 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: letrozole 2.5 mg daily (Group C)
Trial: 12090818
Drug: Desipramine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desipramine (mean total daily dose, 3.4 mg/kg per day)
Trial: 10613165
Drug: Transcutaneous electrical
RxNorm normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcutaneous electrical nerve stimulation as analgesic and exercise
Trial: 25392341
Drug: Dexmedetomidine 4
RxNorm normalized name: DEXMEDETOMIDINE 4MCG/ML/NS INJ BAG 50ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 4 µg/cc
Trial: 25392341
Drug: Dexmedetomidine 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 8 µg/cc
Trial: 24811963
Drug: Aganirsen eye
RxNorm normalized name: Aganirsen
DrugBank: Aganirsen (DB15369)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aganirsen eye drops (86 μg/day/eye) applied twice daily for 90 days
Trial: 19151567
Drug: 5'‐DFUR for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5'‐DFUR for postoperative 10 months (1,200 mg/body/day for five days followed by two days rest)
Trial: 2448145
Drug: Combination doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination doxorubicin and mitomycin C (DM)
Trial: 2448145
Drug: Combination cisplatin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination cisplatin, vinblastine and bleomycin (PVB)
Trial: 30943497
Drug: Bromazepam 3
RxNorm normalized name: bromazepam 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromazepam 3 mg plus Propranolol 40 mg
Trial: 29208690
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated equine estrogen (0.45 mg/day), n=18
Trial: 29208690
Drug: Transdermal 17β-estradiol
RxNorm normalized name: 17β-estradiol
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal 17β-estradiol (50 μg/day) with oral micronized progesterone (Prometrium 200 mg), n=23
Trial: 29208690
Drug: Placebo pills
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pills and patch, n=26
Trial: 25488344
Drug: DC group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DC group (double-coated probiotic formulation)
Trial: 25488344
Drug: NC group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NC group (non-coated probiotic formulation)
Trial: 21507257
Drug: Structured interview
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured interview followed by visits every 2-3 weeks to the end of dose reduction
Trial: 21507257
Drug: Structured interview
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured interview plus delivery of written instructions to self-reduce benzodiazepine dose
Trial: 18713842
Drug: Metyrapone (METY,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metyrapone (METY, 3 g)
Trial: 18713842
Drug: Ketoconazole (KTCZ,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole (KTCZ, 1.2 g)
Trial: 12816022
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care (including medical record review, medication history review, pharmacotherapeutic evaluation, patient medication education and monitoring over one year)
Trial: 9199125
Drug: Theophylline (3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (3.5 mg/kg) administered intravenously to humans with mixed-form hyperlipidemia
Trial: 9199125
Drug: Theophylline (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (12 mg/kg) administered intravenously to hyperlipidemic rabbits
Trial: 6849784
Drug: Intravenous chloroquine
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous chloroquine (300 mg)
Trial: 6849784
Drug: Oral solution
RxNorm normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral solution chloroquine (300 mg)
Trial: 6849784
Drug: Chloroquine tablets
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine tablets (300 mg)
Trial: 6849784
Drug: Oral doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral doses of chloroquine
Trial: 27365077
Drug: Genta‐Coll group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genta‐Coll group (G‐group)
Trial: 22586827
Drug: Treatment-control (table
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-control (table stabilization)
Trial: 15592329
Drug: Fluconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (200 mg daily) with Dapsone (100 mg daily)
Trial: 15592329
Drug: Rifabutin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifabutin (300 mg daily) with Dapsone (100 mg daily)
Trial: 15592329
Drug: Fluconazole plus
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole plus Rifabutin with Dapsone (100 mg daily)
Trial: 15592329
Drug: Clarithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (500 mg twice daily) with Dapsone (100 mg daily)
Trial: 15592329
Drug: Dapsone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapsone (100 mg daily) alone
Trial: 11359439
Drug: HAART (Highly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAART (Highly Active Antiretroviral Therapy) for 12 months
Trial: 9644873
Drug: 300 mg/day
RxNorm normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg/day of ZAM
Trial: 3218660
Drug: 1 alpha(OH)D3
RxNorm normalized name: 1-alpha-25-Dihydroxyvitamin D3
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 alpha(OH)D3 treatment (2 micrograms for 3 months)
Trial: 27785091
Drug: Botulinum toxin‐A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin‐A (BTX‐A) injection
Trial: 21346512
Drug: Once-daily DRV/r
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily DRV/r 800/100 mg
Trial: 21346512
Drug: Twice-daily DRV/r
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-daily DRV/r 600/100 mg
Trial: 10894321
Drug: Enalapril 5-20
RxNorm normalized name: enalapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 5-20 mg od
Trial: 10894321
Drug: Nifedipine 30-90
RxNorm normalized name: nifedipine 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 30-90 mg od
Trial: 7402771
Drug: Oral salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral salbutamol (0.15 mg/kg)
Trial: 7402771
Drug: Salbutamol aerosol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol aerosol (0.2 mg)
Trial: 30481106
Drug: Commercial scale
RxNorm normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercial scale (CS) vaccine lot 1
Trial: 30481106
Drug: Commercial scale
RxNorm normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercial scale (CS) vaccine lot 2
Trial: 30481106
Drug: Commercial scale
RxNorm normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercial scale (CS) vaccine lot 3
Trial: 30481106
Drug: Licensed pilot
RxNorm normalized name: Picot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licensed pilot scale (LPS) vaccine
Trial: 19445861
Drug: Dexamethasone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.5 mg/kg)
Trial: 8703690
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy (20 Gy in five fractions)
Trial: 2127786
Drug: Interferon (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon (2 million units, subcutaneous injections three times weekly for 6 months)
Trial: 2127786
Drug: Placebo (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (subcutaneous injections three times weekly for 6 months)
Trial: 10682943
Drug: Symptom-limited exercise
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptom-limited exercise testing for peak oxygen consumption (VO2peak, mL/kg/min)
Trial: 8656171
Drug: Erythromycin 250
RxNorm normalized name: erythromycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 250 mg four times daily for 10 days
Trial: 1672176
Drug: ICI 204.219
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 204.219 (40 mg single oral dose)
Trial: 6307464
Drug: Intravenous acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous acyclovir 5 mg/kg twice daily during granulocytopenia
Trial: 31977370
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg chlorzoxazone 3 times daily for the first 7 days postoperatively
Trial: 26434934
Drug: AMG 151
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 151 (50, 100, or 200mg twice daily)
Trial: 26434934
Drug: AMG 151
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 151 (100, 200, or 400mg once daily)
Trial: 24225595
Drug: Low-dose whey
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose whey protein isolate (0.8 g·kg1·d1; W1)
Trial: 24225595
Drug: High-dose whey
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose whey protein isolate (1.6 g·kg1·d1; W2)
Trial: 22423128
Drug: Linezolid (exact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linezolid (exact dosage and duration not specified)
Trial: 15058116
Drug: Lignocaine with
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignocaine with 5 ml saline (Control Group L)
Trial: 11407430
Drug: Indirectly related
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indirectly related words (e.g., sofa) used as primes for low-frequency inconsistent words in naming tasks.
Trial: 11407430
Drug: Indirectly related
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indirectly related words (e.g., sofa) used as primes for high-frequency inconsistent words in a speeded naming task.
Trial: 3306500
Drug: Intravenously administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenously administered cefuroxime and metronidazole (three-dose perioperative course)
Trial: 29371115
Drug: Sedation administered
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sedation administered in treatment groups
Trial: 23394782
Drug: Controlled ovarian
RxNorm normalized name: modified Vaccinia Ankara-Bavarian Nordic Injection [Jynneos]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled ovarian stimulation with highly purified human menopausal gonadotropin (hphMG) or recombinant FSH in a GnRH antagonist cycle.
Trial: 7628032
Drug: Oral clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral clonidine (5 micrograms.kg-1)
Trial: 1974498
Drug: S(−)‐CARV after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S(−)‐CARV after i.v. administration
Trial: 1974498
Drug: R(+)‐CARV after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R(+)‐CARV after i.v. administration
Trial: 1974498
Drug: S(−)‐CARV after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S(−)‐CARV after p.o. administration
Trial: 1974498
Drug: R(+)‐CARV after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R(+)‐CARV after p.o. administration
Trial: 31174586
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIG) followed by rituximab
Trial: 31174586
Drug: Placebo infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusions of 1% albumin followed by 0.9% sodium chloride
Trial: 27085996
Drug: EPA +
RxNorm normalized name: Eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EPA + DHA supplementation (600 mg EPA and 260 mg DHA per day)
Trial: 24775812
Drug: Ciprofloxacin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (10 doses of 500 mg every 12 hours during 5 days)
Trial: 24775812
Drug: Fosfomycin-trometamol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosfomycin-trometamol (2 doses of 3g every 48 hours)
Trial: 18363884
Drug: GH-treatment (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH-treatment (1 mg/m²/day) in infants (n=20) for 1 year
Trial: 18363884
Drug: GH-treatment (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH-treatment (1 mg/m²/day) in children > 3 years (n=27) for 2 years
Trial: 18363884
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment) in infants (n=22) for 1 year
Trial: 18363884
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment) in children > 3 years (n=22) for 2 years
Trial: 18363884
Drug: GH-treatment (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH-treatment (1 mg/m²/day) in infants and children
Trial: 18363884
Drug: GH-treatment (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH-treatment (1 mg/m²/day) in children
Trial: 15957834
Drug: Sodium ferulate
RxNorm normalized name: ferulate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium ferulate (SF) treatment for 4 weeks
Trial: 7703389
Drug: L-Arginine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Arginine (5 mg/kg per minute for 90 min)
Trial: 7703389
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of endothelin and L-arginine
Trial: 373560
Drug: Administration sets
RxNorm normalized name: administration sets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration sets changed every 24 hours
Trial: 373560
Drug: Administration sets
RxNorm normalized name: administration sets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration sets changed every 48 hours
Trial: 30037647
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis once daily for 12 months
Trial: 20178563
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg daily for 8 weeks and 10 mg for the next 4 months (AF group)
Trial: 20178563
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg daily for 8 weeks and 10 mg for the next 4 months (non-AF group)
Trial: 17503876
Drug: Exercise training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise training and supplements (oxygen, oral creatine, anabolic steroids and polyunsaturated fatty acids)
Trial: 16037110
Drug: Sublingual misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual misoprostol 400 mg every 3 h for a maximum of five doses
Trial: 16037110
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol 400 mg every 3 h for a maximum of five doses
Trial: 7748753
Drug: Terbinafine 250
RxNorm normalized name: terbinafine 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine 250 mg/day for 2 weeks
Trial: 7748753
Drug: Itraconazole 100
RxNorm normalized name: itraconazole 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 100 mg/day for 4 weeks
Trial: 24427672
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate 200 mcg/day plus oral Levocetirizine 5 mg/day (n: 21)
Trial: 24427672
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate 200 mcg/day plus oral Montelukast 10 mg/day (n: 21)
Trial: 24427672
Drug: Topical Mometasone
RxNorm normalized name: mometasone Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Mometasone furoate 200 mcg/day (n: 14)
Trial: 21088253
Drug: Atazanavir treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir treatment (3-day duration)
Trial: 18440147
Drug: 40% menthol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40% menthol solution
Trial: 18440147
Drug: 20% cinnamaldehyde
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% cinnamaldehyde solution
Trial: 16848645
Drug: Bupropion XL
RxNorm normalized name: Bupropion Hydrochloride 150 MG Oral Tablet, Extended Release [BUPROPION XL]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion XL 300 to 450 mg/day
Trial: 14572572
Drug: Mesalamine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalamine (4 g o.d.)
Trial: 10846036
Drug: n-3 fatty
RxNorm normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 fatty acid supplementation at 4 g/day
Trial: 10846036
Drug: Control trial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control trial (fat meal, 100 g fat)
Trial: 2878747
Drug: SMS 201-995,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMS 201-995, 50 micrograms, twice daily subcutaneous injection
Trial: 30373463
Drug: DREAMS:START intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DREAMS:START intervention to improve sleep for people living with dementia; details on dosage and duration not specified.
Trial: 27274151
Drug: Herbal oral
RxNorm normalized name: Sucrets Herbal Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal oral rinse
Trial: 22944595
Drug: Twelve Step
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Twelve Step Facilitation (TSF) treatment
Trial: 20965928
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg erythromycin once daily for 12 weeks
Trial: 6425917
Drug: Standard tricyclic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard tricyclic antidepressants
Trial: 30852547
Drug: Ticagrelor monotherapy
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor monotherapy (90 mg twice daily) after 1-month DAPT
Trial: 30852547
Drug: Standard regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard regimen of DAPT for 12 months followed by aspirin monotherapy
Trial: 28884877
Drug: Self-administered acupressure
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered acupressure (n=15)
Trial: 16225499
Drug: Nifuratel (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifuratel (15 mg/kg/day, q.d.s.)
Trial: 16225499
Drug: Furazolidone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furazolidone (10 mg/kg/day, q.d.s.)
Trial: 8527292
Drug: MK-0476 20
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0476 20 to 800 mg single oral doses
Trial: 8527292
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg MK-0476 as a solution
Trial: 8527292
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg MK-0476 capsules after a standard breakfast
Trial: 1526087
Drug: Aspirin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (100 mg/ml) in methyl cellulose gel
Trial: 28924018
Drug: Ibrutinib (420
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib (420 mg daily)
Trial: 20090348
Drug: Thermoreversible wound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thermoreversible wound gel containing polyhexanide
Trial: 18362418
Drug: Aggressive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive therapy aiming for targets of <120/80 mmHg and <80 mg/dl for blood pressure and LDL-C respectively.
Trial: 18362418
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy aiming for blood pressure <140/90 mmHg and LDL-C <100 mg/dl.
Trial: 31462727
Drug: Soursop supplementation
RxNorm normalized name: soursop extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soursop supplementation (2 × 100 g soursop fruit juice per day for 3 months)